June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Repeated dosing of NCX 667, a new nitric oxide (NO) donor, retains IOP-lowering activity in animal models of glaucoma
Author Affiliations & Notes
  • Elena Bastia
    Nicox Research Institute, Bresso, Italy
  • Francesco Impagnatiello
    Nicox Research Institute, Bresso, Italy
  • Ennio Ongini
    Nicox Research Institute, Bresso, Italy
  • Janet B Serle
    Icahn School of Medicine at Mount Sinai, New York , New York, United States
  • Michael V W Bergamini
    Nicox Ophthalmics, Inc, Fort Worth, Texas, United States
  • Footnotes
    Commercial Relationships   Elena Bastia, Nicox Research Institute (E); Francesco Impagnatiello, Nicox Research Institute (E); Ennio Ongini, Nicox Research Institute (E); Janet Serle, NicoX Research Institute (F); Michael Bergamini, Nicox Ophthalmics Inc (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 2106. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Elena Bastia, Francesco Impagnatiello, Ennio Ongini, Janet B Serle, Michael V W Bergamini; Repeated dosing of NCX 667, a new nitric oxide (NO) donor, retains IOP-lowering activity in animal models of glaucoma. Invest. Ophthalmol. Vis. Sci. 2017;58(8):2106.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : NCX 667 is a novel NO-donor proven to effectively lower intraocular pressure (IOP) in rabbit and non-human primate models of glaucoma after single administration. Here we address the IOP-lowering effect of NCX 667 after repeated dosing.

Methods : NCX 667 (1%, 30μL dissolved in PBS with cremophor EL 5%, DMSO 0.3%, BAC 0.02%) was administered 4 consecutive times 1 hour apart within 1 day or bid (9AM & 4PM) for 5 days to ocular normotensive New Zealand White rabbits. IOPs were recorded prior to dosing and hourly post-dosing in the first study or 30, 60, 120, 180, and 240min post AM dose on days 1, 3 and 5 in the second study. Laser-induced ocular hypertensive non-human primates were treated bid (9AM & 4PM) for 5 consecutive days and IOPs measured hourly for 6 hours on days 1, 3 and 5. Two-way ANOVA followed by Bonferroni’s multiple comparison test was performed as statistical analysis.

Results : In rabbits, NCX 667 resulted in sustained IOP-lowering when administered hourly during 4h (IOP change= -3.11 ± 0.72 and -3.11± 0.74 mmHg, 30-60 min following the first and the fourth administration, respectively). Similarly, on day 1, NCX 667 AM dose rapidly lowered IOP (IOP change= -3.6 ± 1.0 mmHg, p<0.05 vs. vehicle at 30min), and slowly returned to baseline values of 21.2 ± 0.2 mmHg at 240min. NCX 667 was as effective on day 3 (IOP change= -2.7 ± 0.4 mmHg, 30min) and 5 (IOP change= -3.9 ± 0.5 mmHg, 30min) compared to day 1. No signs of ocular discomfort were observed. Similarly, in the primates NCX 667 retained its IOP-lowering effects over 5 days of treatment (IOP change= -8.5 ± 5.6 mmHg, day 1 and -8.6 ± 4.5 mmHg, day 5).

Conclusions : Regardless of the experimental paradigm used, repeated dosing with NCX 667 resulted in comparable IOP-lowering activity over time with no signs of tachyphylaxis or ocular discomfort.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×